Compare Live Nation Entertainment, Inc. (LYV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Merck & Co., Inc. — how do they compare? Live Nation Entertainment, Inc. trades at $172.14 (market cap $39.92B), while Merck & Co., Inc. trades at $145 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 8.8× Live Nation Entertainment, Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Merck & Co., Inc. for 98 Days on average.
| LYV | MRK | |
|---|---|---|
Market Cap | $39.92B | $351.28B |
Volume | 1,982,609 | 7,969,665 |
Sector | Media | Health |
52-Week High | $188.46 | $156.43 |
52-Week Low | $125.61 | $82.49 |
Typical Hold Time | 72 Days | 98 Days |
Enterprise Value | $42.13B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $170.84, down 0.55% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 earnings beat with 1.05 EPS versus 0.66 expected, though Q1 and Q4 2025 missed estimates. Revenue growth continues with $25.2B in 2025, while net income margin remains thin at 0.51%. Analyst consensus is strongly bullish with 87% buy ratings and a $208.18 price target, representing 22% upside potential.
LYV benefits from strong consumer demand for live events ('funflation' trend) and record deferred revenue of $6.4B, but faces execution risks from cost pressures, legal uncertainties, and high debt levels. The stock's elevated P/E of 117.5 reflects growth expectations, making it sensitive to earnings delivery. Near-term support sits at $169 with resistance at $172.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
